Avalyn Pharma Inc. reported financial results for the quarter ended June 30, 2026, reporting a net loss of $28.9 million compared to $20.2 million in the prior year period. Research and development expenses increased to $24.7 million from $17.9 million, while general and administrative expenses rose to $6.6 million from $3.9 million. The company ended the quarter with $413.5 million in cash, cash equivalents, and marketable securities, projecting a cash runway into 2029. Clinically, Avalyn completed enrollment of its global Phase 2b MIST trial for AP01 with 398 patients, with topline data expected in the second half of 2027. The company operates as a clinical-stage biopharmaceutical firm developing inhaled therapies for rare respiratory diseases.
